Lite Strategy, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $38.9M
- Price
- $1.28
- % Change (Daily % change from the live per-ticker quote feed.)
- -9.22%
- Volume
- 233.1K
About
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
Quick stats
Shares outstanding30.4M
Computed float29.7M
Float / shares97.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001262104
Websitehttps://www.litestrategy.com
AI Summary
AI-generated1/7
standardbullishearnings
Lite Strategy Reports Fiscal Year 2026 Financial Results
Lite Strategy reported fiscal year 2026 results, its first full year running a Litecoin treasury strategy after deploying $100 million to acquire over 900,000 LTC.
As of June 30, 2026 the company held 832,716 LTC, ran a covered call program that generated roughly $930,000 in premium proceeds, and repurchased 6.4 million shares (17% of shares outstanding) through September 22, halving its NAV discount from the low 40% range to the low 20% range.
The company ended the fiscal year with $5.7 million in cash, $34.9 million in unrestricted digital assets, total assets of $42.7 million and no debt.
Management's stated focus going forward is growing LTC per share via accretive buybacks, expanded yield opportunities, and lower burn, supported by SEC/CFTC guidance treating LTC as a digital commodity.
Red flags
- no revenue or EPS disclosed for fiscal 2026 — value driven entirely by LTC price and NAV discount
- company explicitly flags Nasdaq listing compliance risk and LTC price volatility
- potential dilution from outstanding warrants and options
- small cash balance ($5.7M) relative to operating costs and 'lower cash burn' objective